Stockscreener 앱 받기
0.53%
시간 외 거래:
Amgen Inc 주식(AMGN)의 최신 뉴스
Ex-Dividend Reminder: Cencora, Amgen and Oppenheimer Holdings - Nasdaq
Amgen (NASDAQ:AMGN) Price Target Raised to $295.00 - MarketBeat
Rhumbline Advisers Sells 6,685 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.52 - simplywall.st
Prospera Financial Services Inc Sells 6,723 Shares of Amgen Inc. $AMGN - MarketBeat
Caprock Group LLC Makes New Investment in Amgen Inc. $AMGN - MarketBeat
Wealthfront Advisers LLC Grows Stock Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Stock Holdings Reduced by Allegheny Financial Group - MarketBeat
How Amgen Inc. (AMGN) Affects Rotational Strategy Timing - Stock Traders Daily
AstraZeneca Unit Settles Soliris Feud With Samsung, Amgen - Law360
Mizuho Raises Price Target on Amgen to $295 From $280, Keeps Outperform Rating - marketscreener.com
Daiwa Securities Group Forecasts Strong Price Appreciation for Amgen (NASDAQ:AMGN) Stock - MarketBeat
Just Two Days Till Amgen Inc. (NASDAQ:AMGN) Will Be Trading Ex-Dividend - 富途牛牛
United States Biotechnology Market to hit US$ 1.5 Trillion - openPR.com
Two Days Left Until Amgen Inc. (NASDAQ:AMGN) Trades Ex-Dividend - simplywall.st
Daiwa Securities Adjusts Price Target on Amgen to $410 From $370, Maintains Outperform Rating - marketscreener.com
The 5 Most Interesting Analyst Questions From Amgen's Q4 Earnings Call - Finviz
The 5 Most Interesting Analyst Questions From Amgen’s Q4 Earnings Call - The Globe and Mail
Alps Advisors Inc. Has $5.29 Million Stake in Amgen Inc. $AMGN - MarketBeat
Wesbanco Bank Inc. Increases Stake in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Amgen stands by vasculitis drug Tavneos after FDA wants it pulled - ANCA Vasculitis News
When Advocacy Meets Science in the Care of People Living with gMG - Amgen
Amgen, Merck share losses contribute to Dow's 200-point drop - MSN
Amgen Inc. (AMGN) is attracting investor attention: Here is what you should know - MSN
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know - Yahoo Finance
Candriam S.C.A. Cuts Holdings in Amgen Inc. $AMGN - MarketBeat
ProShare Advisors LLC Sells 158,994 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen stock jumps to a 52-week high; here’s what to watch before Monday’s open - TechStock²
Kinsale Capital Group Inc. Has $9.65 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Bessemer Group Inc. Acquires 2,967 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen stock price hits 52-week high after Friday rally — what to watch into Monday - TechStock²
The Truth About Amgen Inc.: Is This Quiet Biotech Giant Your Next Power Move? - AD HOC NEWS
Amgen’s Stock Is Already Up 14% in 2026: Why Analysts Expect $440 - TIKR.com
Twin Capital Management Inc. Sells 5,541 Shares of Amgen Inc. $AMGN - MarketBeat
Renaissance Group LLC Lowers Position in Amgen Inc. $AMGN - MarketBeat
SBI Securities Co. Ltd. Has $977,000 Stock Holdings in Amgen Inc. $AMGN - MarketBeat
$1000 Invested In Amgen 15 Years Ago Would Be Worth This Much Today - Sahm
Amgen (NASDAQ:AMGN) Lowered to "Buy" Rating by Wall Street Zen - MarketBeat
CVS Health to drop Amgen and Lilly's bone disease treatments from some drug lists - Reuters
P/E Ratio Insights for Amgen - Benzinga
Amgen (AMGN) Sees Target Price Increase by Argus Research | AMGN Stock News - GuruFocus
CVS Caremark Replaces Amgen And Eli Lilly's Branded Drugs, Expands Biosimilar Strategy For Weak Bone Disorder - Benzinga
Argus Forecasts Strong Price Appreciation for Amgen (NASDAQ:AMGN) Stock - MarketBeat
Amgen Advances Xaluritamig Into Early-Stage Trial for Hard-to-Treat Ewing Sarcoma - TipRanks
Amgen (AMGN) Target Price Raised by Guggenheim Analyst | AMGN St - GuruFocus
Amgen (NASDAQ:AMGN) Price Target Raised to $347.00 - MarketBeat
Guggenheim Adjusts Price Target on Amgen to $347 From $305, Maintains Neutral Rating - marketscreener.com
Argus Research Adjusts Price Target on Amgen to $400 From $360, Maintains Buy Rating - marketscreener.com
Aurdan Capital Management LLC Sells 5,316 Shares of Amgen Inc. $AMGN - MarketBeat
3,190 Shares in Amgen Inc. $AMGN Acquired by ABN AMRO Bank N.V. - MarketBeat
Biotechnology Market Set to Witness Significant Growth by 2026-2033 | Amgen Inc., GlaxoSmithKline - EIN News
Anti-Obesity Drugs Market to Reach US$195.99 Billion by 2036 as GLP-1 Therapies Drive a Structural Shift in Weight Management - GlobeNewswire Inc.
Cancer Supportive Care Drugs Market Is Going to Boom | Amgen Inc., - openPR.com
Amgen Earnings Call: Broad Growth Amid Manageable Risks - The Globe and Mail
Amgen Refocuses Portfolio As Eczema Exit And Tavneos Review Raise Questions - Yahoo Finance
CVS Health to drop Amgen and Lilly's bone disease treatments from some drug lists (February 5) - marketscreener.com
CVS Health to drop Amgen and Lilly’s bone disease treatments from some drug lists - WKZO
Key facts: Amgen's stock soars 8% on strong earnings; CVS to drop Prolia - TradingView
RBC Lifts Amgen (AMGN) Target After Strong Q4, Cites Key Drug Momentum - Finviz
CVS Health to swap Amgen and Lilly’s bone drugs with biosimilars in commercial formularies - Seeking Alpha
Amgen’s IMLYGIC Safety Study in Melanoma Reaches Completion: What Investors Should Watch - TipRanks
These 2 Companies Could Soon Join the Weight Loss Market: Are They Buys? - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Pfizer (PFE) and Merck & Company (MRK) - The Globe and Mail
Amgen Benefits From US Biosimilar Monopoly With $700m Sales For Pavblu - Citeline News & Insights
5.82%
0.77%
자본화:
|
볼륨(24시간):